Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules
Antibody drug conjugates offer a niche opportunity in drug development and contract manufacturing.


Pharmaceutical Technology



Patricia Van Arnum
Targeted therapies such as monocolonal antibodies are an important part of anticancer drug development. Humanized antibodies may be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, or toxins to create highly targeted agents. Antibody drug conjugates (ADCs), or monoclonal antibodies linked to a cytotoxic small molecule, provide a niche opportunity for biopharmaceutical companies and contract manufacturers.

Monclonal antibodies target cancer

Six engineered monoclonal antibodies ["Rituxan" (rituximab), "Herceptin" (trastuzumab), "Campath" (alemtuzumab), "Avastin" (bevacizumab), "Erbitux" (cetuximab), and "Vectibix" (panitumumab)], two radionuclide-conjugated monoclonal antibodies ["Zevalin" (ibritumomab tiuxetan) and "Bexxar" (tositumomab; iodine I 131 tositumomab)], and one ADC ["Mylotarg" (gemtuzumab ozogamicin)] have been approved to treat cancer (1).


Figure 1: "Mylotarg" (gemtuzumab ozogamicin) is an antibody drug conjugate. It is composed of a recombinant humanized IgG4 kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora subspecies calichensis.
Wyeth's (Madison, NJ) Mylotarg is the only ADC approved by the US Food and Drug Administration. The drug was approved in 2000. Mylotarg consists of a recombinant humanized IgG4 kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora subspecies calichensis (see Figure 1). The antibody portion of Mylotarg binds specifically to the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and immature normal cells of myelomonocytic lineage, but not on normal hematopoietic stem cells. The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line and is purified under conditions which remove or inactivate viruses. Three separate and independent steps in the hP67.6 antibody purification process achieves retrovirus inactivation and removal. These include low pH treatment, diethylaminoethyl (DEAE)-"Sepharose" chromatography, and viral filtration. Mylotarg's amino-acid sequences are 98.3% of human origin. The constant and framework regions contain human sequences. The complementarity-determining regions are derived from a murine antibody (p67.6) that binds CD33. This antibody is linked to N-acetyl-gamma calicheamicin via a bifunctional linker. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with four to six moles calicheamicin per mole of antibody. The remaining 50% of the antibody is not linked to the calicheamicin derivative (2).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here